The Warwick Hip Trauma Evaluation One - an abridged protocol for the WHiTE One Study AN EMBEDDED RANDOMISED TRIAL COMPARING THE X-BOLT WITH SLIDING HIP SCREW FIXATION IN EXTRACAPSULAR HIP FRACTURES by Griffin, XL et al.
VOL. 2, No. 10, OCTOBER 2013 206
 TRAUMA
The Warwick Hip Trauma Evaluation One 
– an abridged protocol for the WHiTE 
One Study
AN EMBEDDED RANDOMISED TRIAL COMPARING THE X-BOLT WITH 









 X. L. Griffin, MRCS, PhD, NIHR 
Clinical Lecturer
Warwick Orthopaedics, Warwick 
Medical School, University of 
Warwick, Coventry CV4 7AL, UK, 
and University Hospitals 
Coventry and Warwickshire NHS 
Trust, Clifford Bridge Road, 
Coventry CV2 2DX, UK.
 J. McArthur, FRCS(Tr & Orth), 
Specialty Registrar
University Hospitals Coventry 
and Warwickshire NHS Trust, 
Clifford Bridge Road, Coventry 
CV2 2DX, UK.
 J. Achten, PhD, Research 
Manager
Warwick Orthopaedics, Warwick 
Medical School, University of 
Warwick, Coventry CV4 7AL, UK.
 N. Parsons, PhD, Statistician
Warwick Medical School, 
University of Warwick, Coventry 
CV4 7AL, UK.
 M. L. Costa, PhD, FRCS(Tr & 
Orth), Professor
Warwick Medical School, Clinical 
Trials Unit, University of Warwick, 
Coventry CV4 7AL, UK, and 
University Hospitals Coventry 
and Warwickshire NHS Trust, 
Clifford Bridge Road, Coventry 
CV2 2DX, UK.
Correspondence should be sent 




Bone Joint Res 2013;2:206–9. 
Received 8 May 2013; Accepted 
after revision 4 July 2013
Fractures of the proximal femur are one of the greatest challenges facing the medical 
community, constituting a heavy socioeconomic burden worldwide. Controversy exists 
regarding the optimal treatment for patients with unstable trochanteric proximal femoral 
fractures. The recognised treatment alternatives are extramedullary fixation usually with a 
sliding hip screw and intramedullary fixation with a cephalomedullary nail. Current 
evidence suggests that best results and lowest complication rates occur using a sliding hip 
screw. Complications in these difficult fractures are relatively common regardless of type of 
treatment. We believe that a novel device, the X-Bolt dynamic plating system, may offer 
superior fixation over a sliding hip screw with lower reoperation risk and better function. We 
therefore propose to investigate the clinical effectiveness of the X-bolt dynamic plating 
system compared with standard sliding hip screw fixation within the framework of a the 
larger WHiTE (Warwick Hip Trauma Evaluation) Comprehensive Cohort Study.
Cite this article: Bone Joint Res 2013;2:206–9.
Introduction
Fracture of the proximal femur is one of the
greatest challenges facing the medical com-
munity. In 1990, a global incidence of
1.31 million was reported, associated with
740 000 deaths.1 Proximal femoral fractures
constitute a heavy socioeconomic burden
worldwide. The cost of this clinical problem is
estimated at 1.75 million disability adjusted
life years lost, and 1.4% of the total healthcare
burden in established market economies.1
Fixation using the sliding hip screw (SHS) is
well established in the treatment of extracap-
sular fractures. In the majority of relatively
stable fractures it is very effective at allowing
controlled collapse of the fracture, leading to
mechanical stability and subsequent union.2
However, unstable fractures of the proximal
femur often present with too much commi-
nution and deficient bone to share load with
the fixation device. Rather than controlled
collapse along the line of the screw, the frac-
ture may collapse into varus with cut-out of
the screw from the head, necessitating more
complex revision surgery.3
The X-Bolt dynamic plating system (X-Bolt
Orthopaedics, Dublin, Ireland) builds on the
successful design features of the SHS by using
a plate attached to the lateral femur and a
single telescoping screw in the femoral head,
but differs in the nature of the fixation in the
head. Expanding flanges are deployed to
engage and compress the surrounding can-
cellous bone, thereby improving fixation.4
Unstable trochanteric fractures rely more on
the quality of fixation in the femoral head to
prevent cut-out and the poor bone quality
encountered in the patients sustaining these
fractures often contributes to failure.
The aim of this trial is to investigate the clin-
ical effectiveness of the X-bolt dynamic plat-
ing system compared with the sliding hip
screw in the treatment of unstable trochan-
teric fractures of the proximal femur.
Patients and Methods
Study design. This will be a single-centre,
multi-surgeon, parallel, two-arm, standard-
of-care randomised controlled clinical trial. It
will be embedded within the WHiTE Compre-
hensive Cohort Study.5 The study will include
a two-way superiority comparison between
X-Bolt dynamic plating system and SHS.
Ethical approval. This study has been
reviewed by the National Research Ethics
Service Committee West Midlands – Coven-
try and Warwickshire (12/WM/0352). The
study was given ethical approval on
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6 November 2012. The research will be carried out in
compliance with the Helsinki Declaration.
Study registration. This study has been registered with
the International Standard Randomised Controlled Trial
Number Register (ISRCTN85181068) and the NIHR Com-
prehensive Research Network Portfolio (ID14104).
Study participants. All patients aged ≥ 60 years with an
AO/OTA type A2 and A3 fracture6 of the proximal femur,
including those with cognitive impairment, are eligible
for inclusion in this study. Patients will be excluded if they
are deemed by the Consultant Trauma Surgeon to be
medically unfit for an operation and are treated non-
operatively.
Recruitment. Patients will be recruited from trauma
meetings at University Hospitals Coventry and Warwick-
shire NHS Trust. Pre-enrolment eligibility checks will be
carried out to ensure that participants are not enrolled in
error, and informed written consent will be obtained
once participants regain capacity. Inclusion of the partic-
ipant in the study will be recorded in the clinical notes by
the research associate.
Those participants, or consultees, who do not wish to
participate in the study following the informed consent
discussion, will be withdrawn from the study. Baseline
data and any information about serious adverse events
obtained from this group of patients up until the point of
withdrawal will be included in the final analysis.
Similarly, data of patients who die before consent can
be gained, will be included in the final analysis. For those
patients who lack capacity, and die before agreement can
be obtained from the patients’ relatives/next-of-kin, it is
our intention not to contact relatives of patients to inform
them of the patients’ initial inclusion in the study, in order
to avoid distressing the relatives unnecessarily. For those
patients withdrawing from the trial after written consent
has been obtained, data obtained up until the point of
withdrawal will be included in the final analysis.
Timeline. The study commenced recruitment on 25 Feb-
ruary 2013. Recruitment is planned to last for one year in
the first instance.
Consent. The large majority of patients with fracture of
the proximal femur are a clinical priority for urgent oper-
ative care. They will undergo surgery on the next avail-
able trauma operating list. All patients with a fracture of
the proximal femur are in pain and have received opiate
analgesia. It is therefore understandable that patients
find the initial period of their treatment in hospital con-
fusing and disorientating. Similarly, patients’ next-of-
kin, carers and friends are anxious at this time and may
also have difficulty in weighing the large amounts of
information that they are given about the injury and
plan for treatment.
In this emergency situation the focus is on obtaining
consent for surgery (where possible) and informing the
patient and any next of kin about immediate clinical care.
It is not possible for the patient/consultee to review trial
documentation, weigh the information and communi-
cate an informed decision about whether they would
wish to participate.
Conducting research in this ‘emergency setting’ is reg-
ulated by the Mental Capacity Act 2005 (MCA).7 As
patients are likely to lack capacity as described above, and
because of the urgent nature of the treatment limiting
access to and appropriate discussion with personal con-
sultees, we propose to act in accordance with section 32,
subsection 9b of the MCA following a process approved
by the relevant research ethics committee. Those patients
who have surgery on the next available trauma operating
theatre enter the study under presumed consent; we will
not obtain consent prior to surgery but will endeavour to
inform an appropriate consultee. Where a Personal Con-
sultee is available, they will be provided with the study
information. The Personal Consultee will be given the
opportunity to ask questions and discuss the study after
which their oral agreement will be recorded.
Due to the urgent nature of the treatment limiting
access to and appropriate discussion with Personal Con-
sultees, we will act in accordance with section 32 subsec-
tion 9b of the MCA. Where a Personal Consultee is not
available, a Nominated Consultee will be identified to
advise the research team. The Nominated Consultee will
be the patient’s treating Trauma and Orthopaedic Sur-
geon. If that surgeon is a member of the research team,
another independent surgeon will be identified.
At the first appropriate time when the patient has
regained capacity (this will usually be on the first day after
surgery) the research associate will provide the partici-
pant with all of the study information. The participant
will be given the opportunity to ask questions and dis-
cuss the study with their family and carers. They will then
be asked to provide written consent for continuation in
the study.
Rarely, some patients may be able to consent before
their operation, namely those whose surgery has been
delayed for clinical reasons. These patients will be
approached by the research team before their operation
for consent to participate in the study. Some patients,
whose surgery has been delayed, may still not have
capacity, e.g. those who are acutely confused. If the clin-
ical team in charge of that patient’s care do not think that
the patient is able to provide clinical consent for their
operation, then the research team will approach a con-
sultee for agreement that the patient participate in the
study. The patient themselves will be approached for con-
sent as soon as the clinical team deem that they have
regained capacity following their operation.
For participants who do not regain capacity or lack
capacity, reasonable efforts will be made to identify a Per-
sonal Consultee as described in the Mental Capacity Act
2005. If no Personal Consultee can be identified then a
Nominated Consultee will be identified to advise the
research team. 
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At all times the Chief Investigator will act in accordance
with the patients’ best interests.
Best efforts will be made to involve participants who,
temporarily or permanently, lack capacity in the decision
to be involved in the study. The clinical team will make a
judgement about the amount and complexity of the
information that the participant is able to understand and
retain on an individual basis. Appropriate information will
be communicated to the participant and updated as their
understanding changes.
Any new information that arises during the trial that
may affect participants’ willingness to take part will be
reviewed by the Trial Steering Committee; if necessary
this will be communicated to all participants. A revised
consent form will be completed if necessary.
Responsibility for recording and dating both oral and
written informed consent or agreement will be with the
investigator, or persons designated by the investigator,
who conducted the informed consent discussion. 
Post-recruitment withdrawals and exclusions. Partici-
pants may withdraw from the study at any time without
prejudice. The General Practitioners of those participants
who are ‘lost to follow-up’ will be contacted in order to
attempt to complete the follow-up. Participants may be
withdrawn from the study at the discretion of the Chief
Investigator due to safety concerns.
Treatment allocation
Sequence generation. The allocation sequence will be
generated randomly to achieve a 1:1 ratio using blocks of
variable sizes, stratified by cognitive status.
Allocation concealment. The allocation will be deter-
mined using secure, online randomisation via a distant
computer generated system administered by The Univer-
sity of York (York, United Kingdom).
Allocation implementation. Participants will be enrolled
by the trial research associates. Participants will be
assigned to their treatment allocation prior to the time of
surgery by accessing the online randomisation pro-
gramme. This will allow for treatment allocation to be
implemented outside of working hours.
The surgery will be performed by any of the 16 Consul-
tant Surgeons, two Associate Specialists and 14 Trainees
at the University Hospitals Coventry and Warwickshire
NHS Trust. The large number of surgeons and the wide
skill mix should eliminate the ‘surgeon effect’ such that
stratification by surgeon is not required.
Blinding. Participants will be blinded to the treatment
allocation. The operating surgeon will not be blinded to
the allocation. All clinical outcomes will be assessed by
blinded assessors. Patients will be kept blinded until the
completion of the trial when the blinding is broken.
There will be no formal analysis of the success of the
blinding.
Study treatments. Pre-operative assessment, anaesthetic
technique and post-operative rehabilitation will be
identical to all other participants recruited into the larger
WHiTE Comprehensive Cohort Study.5
Surgical intervention
All participants will have an attempted closed reduction
of their fracture. If satisfactory reduction cannot be
achieved, the surgeon will proceed to open reduction.
The lower limb will be supported on a fracture table.
Internal fixation with either device will be performed fol-
lowing the manufacturers’ guidelines with peri-operative
antibiotic cover in accordance with hospital protocol.
Participants who can tolerate penicillins will receive 1 g
flucloxacillin and 3 mg/kg to 5 mg/kg gentamicin at
induction as an intravenous (IV) infusion over 15 to
30 minutes. Penicillin-sensitive participants will receive
teicoplanin 600 mg, or 800 mg if weight exceeds 80 kg,
as an IV bolus and 3 mg/kg to 5 mg/kg gentamicin as an
IV infusion over 15 to 30 minutes. Those who have a pos-
itive screen for methicillin-resistant Staphylococcus aureus
(MRSA) will be given the same prophylaxis as those who
are penicillin-sensitive.
Participants will be randomly allocated to one of two
groups: 1) sliding hip screw; or 2) X-Bolt dynamic plating
system.
Group 1: Sliding hip screw. Fixation will involve a SHS
with a plate as long as the surgeon feels necessary to
achieve adequate fixation in the femoral shaft. The use of
supplementary fixation such as wires, cables, lag screws
and trochanteric stabilisation plate attachments is permit-
ted at the surgeon’s discretion.
Group 2: X-Bolt dynamic plating system. Fixation will
involve an X-Bolt dynamic plating system following the
manufacturer’s guidelines. A four- or six-hole plate will be
used as the surgeon feels necessary to achieve adequate
fixation in the femoral shaft. Supplementary fixation with
wires, cables and lag screws is permitted at the surgeon’s
discretion.
Follow-up 
Schedule. Participant outcomes will be assessed at base-
line (pre-injury status recorded upon admission to hospi-
tal) and at four, 16 and 52 weeks.
Measures of clinical effectiveness. The primary outcome
will be the EuroQol 5-Dimension (EQ-5D)8 measure of
general health. Secondary outcomes will include the
Oxford hip score,9 ICEpop CAPability measure for Older
people (ICECAP(O)),10 mortality risk, revision risk and
cause, and length of index hospital stay.
For those participants with cognitive impairment the
patient-reported outcomes will be limited to the EQ-5D,
which will be reported by an appropriate proxy.
Power and sample size
In the absence of an agreed method to determine sample
sizes for pilot studies we will recruit a convenience sample
of 100 participants; 50 in each of the two study groups.
209 X. L. GRIFFIN, J. MCARTHUR, J. ACHTEN, N. PARSONS, M. L. COSTA
BONE & JOINT RESEARCH
Using a crude approximation for sample size estimates11
and a standard deviation of 0.3 for EQ-5D one year post-
injury as observed for the WHiTE study,12 this gives 80%
power to detect an effect size of 0.17 at the 5% level. This
is a medium standardised effect size13 of approximately
0.6. Based upon the report from the National Hip Fracture
Database (NHFD) we know that approximately
650 fractures of the proximal femur are treated opera-
tively per year at University Hospitals Coventry and War-
wickshire NHS Trust.14 Based on our experience,
approximately 120 of these patients per year would be
eligible for inclusion into this trial. Therefore the trial sam-
ple can be recruited within one year.
Statistical analysis
The primary outcome measure (EQ-5D at one year post-
injury) will be analysed using a two-sided t-test for differ-
ences between SHS (control) and X-Bolt dynamic plating
system (test) on an intention-to-treat basis. It seems likely
that some data may not be available due to death of
patients, lack of completion of individual data items or
general loss to follow-up. Where possible the reasons for
incomplete data will be ascertained and reported. The
nature and pattern of missing data will be carefully con-
sidered – including in particular whether data can be
treated as missing completely at random. If judged
appropriate, missing data will be imputed. The resulting
imputed datasets will be analysed and reported, together
with appropriate sensitivity analyses. Any imputation
methods used for scores and other derived variables will
be carefully considered and justified. Reasons for ineligi-
bility, non-compliance, withdrawal or other protocol vio-
lations will be stated and any patterns summarised. More
formal analysis, for example using logistic regression with
‘protocol violation’ as a response, may also be appropri-
ate and aid interpretation
A subsidiary analysis will use a multiple linear regres-
sion model to investigate the relationship between each
participants’ EQ-5D score at one year and the treatment
arm, age, gender and cognitive impairment for each par-
ticipant. Estimates from the regression model with 95%
confidence intervals will be reported, along with unad-
justed results from t-tests, and inferences made on the
significance of the treatment effect.
Exploratory, hypothesis-generating analyses of all sec-
ondary measures will also be reported. Continuous data
will be summarised with point estimates of mean and
standard deviations; treatment effects will be estimated
using mean differences and reported with 95% confi-
dence intervals using a two-sided t-test for differences
between SHS (control) and X-Bolt dynamic plating
system (test) on an intention-to-treat basis. Categorical
data will be summarised as proportions; treatment effects
will be estimated using risk ratios and reported with 95%
confidence intervals using a chi-squared test for differ-
ences between SHS (control) and X-Bolt dynamic plating
system (test) on an intention-to-treat basis.
The number and temporal pattern of adverse events
will be investigated to assess if these differ between treat-
ment groups. 
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